452 results on '"Garderet, L."'
Search Results
2. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
3. Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma
4. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
5. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
6. 32nd International Austrian Winter Symposium: Zell am See, the Netherlands. 20-23 January 2016
7. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
8. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
9. Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
10. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
11. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
12. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
13. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
14. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice
15. Myeloma Salvage therapy options in 2016: WP29
16. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation
17. Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature
18. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
19. Minor clone provides a reservoir for relapse in multiple myeloma
20. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation
21. International Myeloma Working Group (IMWG) score accuracy in multiple myeloma patients: need for action
22. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
23. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
24. THIOTEPA-BASED CONDITIONING FOLLOWED BY ALLOGENEIC SCT IN PATIENTS WITH MULTIPLE MYELOMA A SURVEY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT: PH-P531
25. AGE-RELATED TRENDS IN UTILISATION AND OUTCOME OF AUTOLOGOUS HAEMATOPOIETIC CELL TRANSPLANTATION FOR MULTIPLE MYELOMA - A STUDY BY THE PLASMA CELL SUBCOMMITTEE OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY: WP-O012
26. REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA: A COMPARISON OF TANDEM AUTO-ALLOGRAFT TO EARLY REDUCED INTENSITY ALLOGRAFT AS UPFRONT TRANSPLANT: AN EBMT ANALYSIS ON BEHALF OF THE PLASMA CELL DISORDERS: PH-O144
27. HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INDUCES DURABLE REMISSIONS IN PATIENTS WITH POEMS SYNDROME: A RETROSPECTIVE STUDY OF THE PLASMA CELL DISORDERS SUBCOMMITTEE OF THE CHRONIC MALIGNANCY WORKING PARTY OF THE EBMT: PH-O134
28. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
29. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
30. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow
31. Prophylaxis and treatment of graft-versus-host disease: EBMT - ELN working group recommendations for a standardized practice: 296
32. Second allogeneic haematopoietic stem cell transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors: 196
33. Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma - update of the EBMT-NMAM2000 study at 96 months median follow-up: 197
34. Higher probability of survival in complete remission following tandem autologous/reduced-intensity allogeneic transplantation compared to autologous transplantation alone in the NMAM2000 multiple myeloma trial as estimated by multistate models: O158
35. Severe oesophagitis after allogeneic bone marrow transplantation for Fanconi's anemia
36. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization
37. Efficacy and outcome of allogeneic transplantation in rare myeloma: P889
38. Prophylaxis and treatment of graft-versus-host disease after allogeneic stem cell transplantation: a survey of centre strategies by the European Group for Blood and Marrow Transplantation: P443
39. The role of high-dose chemotherapy and autologous stem cell transplantation in patients with poems syndrome: a retrospective study of the MM subcommittee of the Chronic Leukaemia Working Party of the EBMT: 246
40. Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: 0117
41. Corrigendum: Second primary malignancies in multiple myeloma: an overview and IMWG consensus
42. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT: 221
43. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Risk Factors of Early ONJ, Decreased Impact After 2005: A120
44. Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT: A051
45. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone to treat multiple myeloma patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT
46. Reduced versus standard conditioning followed by allogeneic stem cell transplantation in MDS/sAML. A prospective randomised phase III study of the MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplant
47. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect
48. Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia
49. Remission of adult acute lymphocytic leukaemia with Alemtuzumab
50. Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.